Johnson & Johnson (JNJ) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $640.20B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Joaquin Duato |
| IPO Date | 1962-01-02 | CAGR | 6.94% |
| Employees | 141,700 | Website | www.jnj.com |
| Div. Yield | 1.76% | Payout Ratio | 60% |
| Buy Back Yield | 1.1% | Total Yield | 2.86% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $658.31B | P/E | 24.79 | Forward P/E | 20.73 | PEG | -34.32 |
| P/S | 7.45 | P/B | 8.98 | P/CF | 31.88 | P/FCF | 40.33 |
| Sales | $97.93B | Sales 1Y | 8.06% | Sales 3Y | 13.72% | Sales 5Y | 9.8% |
| EPS | $10.73 | EPS 1Y | -7.7% | EPS 3Y | 74.7% | EPS 5Y | 29.77% |
| Sales QoQ | 5.19% | EPS QoQ | 6.07% | Sales QoQ Avg | 1.64% | EPS QoQ Avg | -0.1% |
| Gross Margin | 69.12% | Operating Margin | 26.87% | Profit Margin | 21.83% | ROCE | 18.08% |
| ROA | 10% | ROE | 26% | Altman Z Score | 5.35 | Piotroski Score | 7 |
| Current Ratio | 1.03 | Quick Ratio | 0.77 | Cash Ratio | 0.38 | Op. CF Ratio | 0.04 |
| Debt/Equity | 0.68 | Debt/Assets | 0.27 | Lt Debt/Equity | 0.46 | Lt Debt/Cap. | 0.32 |
| Intrst Cov. | 24.92 | Inventory Turnover | 2.04 | Asset Turnover | 0.48 | Receivables Turnover | 5.44 |
| Enterprise Value | $658.31B | P/E Ratio | 24.79 |
| Forward P/E | 20.73 | PEG Ratio | -34.32 |
| P/S Ratio | 7.45 | P/B Ratio | 8.98 |
| P/CF Ratio | 31.88 | P/FCF Ratio | 40.33 |
| EPS | $10.73 | EPS Growth 1Y | -7.7% |
| EPS Growth 3Y | 74.7% | EPS Growth 5Y | 29.77% |
| Revenue Growth 1Y | 8.06% | Gross Margin | 0.69% |
| Operating Margin | 0.27% | Profit Margin | 0.22% |
| ROE | 0.26% | ROA | 0.1% |
| ROCE | 0.18% | Current Ratio | 1.03 |
| Quick Ratio | 0.77 | Cash Ratio | 0.38 |
| Debt/Equity | 0.68 | Interest Coverage | 24.92 |
| Altman Z Score | 5.35 | Piotroski Score | 7 |
Johnson & Johnson (JNJ) valuation & financials
Johnson & Johnson (JNJ) has a market capitalization of $640.20B and trades at a price-to-earnings ratio of 24.8. It operates in the Healthcare sector (Drug Manufacturers - General).
Johnson & Johnson's revenue grew +8.1% over the last year.
Johnson & Johnson's next earnings report is scheduled for October 13, 2026 before market open; analysts estimate EPS of $3.04.
Johnson & Johnson (JNJ) — frequently asked questions
When does Johnson & Johnson (JNJ) report earnings next?
Johnson & Johnson is expected to report earnings on October 13, 2026 before market open. Analysts estimate EPS of $3.04.
What is Johnson & Johnson's market cap?
Johnson & Johnson (JNJ) has a market capitalization of $640.20B.
What is JNJ's P/E ratio?
Johnson & Johnson trades at a price-to-earnings ratio of 24.8, with trailing twelve-month EPS of $10.73.
How fast is Johnson & Johnson growing?
Johnson & Johnson's revenue grew +8.1% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW) · Novartis (NVS)